The paradox of response and survival in cancer therapeutics - Wikidata - awgldk - TriplyDB

The paradox of response and survival in cancer therapeutics

The paradox of response and survival in cancer therapeutics

http://www.wikidata.org/entity/Q34449433

about

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance Tissue Regeneration in the Chronically Inflamed Tumor Environment: Implications for Cell Fusion Driven Tumor Progression and Therapy Resistant Tumor Hybrid Cells Cancer stem cells: relevance to clinical transplantation Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors Yeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesis Post-genomic clinical trials: the perspective of ACGT Pancreatic cancer.microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers Targeting Hedgehog--a cancer stem cell pathway Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century.Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.Targeting breast cancer stem cells.Cancer stem cells-clinical relevance.From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.Cancer Stem Cells: From Bench to Bedside A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia Concise review: Emerging concepts in clinical targeting of cancer stem cells Heat stress induces epithelial plasticity and cell migration independent of heat shock factor 1.EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer.Cancer induction by restriction of oncogene expression to the stem cell compartment Hypoxia in microscopic tumors.Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.Pin1-Nanog expression in human glioma is correlated with advanced tumor progression.Epithelial stem cells and malignancy.Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.Cancer stem cells: relevance to SCT Therapeutic implications of the cancer stem cell hypothesis.FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies.Cisplatin and TRAIL enhance breast cancer stem cell death Successes, failures and new perspectives of idiotypic vaccination for B-cell non-Hodgkin lymphomas.A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms.Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis.Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG.Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant.Clinical implication of targeting of cancer stem cells.Preclinical development of cancer stem cell drugs.(18)F-fluoromisonidazole PET reveals spatial and temporal heterogeneity of hypoxia in mouse models of human non-small-cell lung cancer.Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers.

P2860

Q24644883-53D31B22-35C0-4AE3-B1AA-B0465EB73EF8 Q26772032-F54F1CFD-EEE6-4AB0-BE53-620C728E76FB Q27008959-54667BBA-FDC6-45CA-9932-B4559AF59695 Q27333860-7A552A13-34E6-401A-A819-5F9611149DB9 Q28481716-93B228D0-6296-4634-947C-A2F84D8B3704 Q28741720-6AC36D2F-E5A3-4EBC-8B73-91F024BEC408 Q30490247-EC16040E-01F9-4F30-9724-2447CFF06012 Q33576814-76803044-95BF-4AAE-B786-061FF2CAA451 Q33925257-04D1E697-8EFC-4AFE-B8E1-850CF7A1A585 Q34037747-0E106A94-7916-4558-B797-4923AB37B28D Q34218232-028980A9-BA4A-4846-BDCF-BF9CF378E749 Q34505105-957E841C-D3EC-4E99-9E57-0BDA09936B44 Q34729707-09862991-4292-4382-954D-5AE5410463C2 Q34978457-B95B0412-5587-49E0-ACBE-DBF9351F741D Q35765724-918F5A04-6360-4262-BC6A-F0A26D67392F Q35885317-F7A81A5B-B69E-44B7-8541-CE203856B188 Q35971159-5FA185C3-B828-4785-A21E-885ABF0B719B Q36309873-05383307-B5EA-4477-A61E-672CBCDEB20D Q36352817-CD7B6D7D-8E54-4614-9664-596CCE9001A0 Q36759364-9039D50E-FDEE-4BD4-87E6-CADC326C3E5F Q37010433-DFC3E489-C753-42FB-824E-89C4CD11B0C6 Q37126963-B1054EA8-0B09-46C4-8E67-559667E109E7 Q37148370-E538897E-035D-4AA3-9B16-28576F97A236 Q37181702-C2AF0D1E-695F-4633-99B4-37FCADCBFA10 Q37220185-4F575F7A-54B1-4B4C-90A0-98CD0F93AB3F Q37325012-72BA9A74-8460-4CCC-9457-1612C79D2B10 Q37398584-27E1BD8F-BDCF-4853-8D91-EEA8D2ED77A9 Q37403285-7ECCB43D-2869-4ED4-8E8C-FD2E57EBCBB5 Q37425433-B4522B10-9747-42C9-BAFD-6E2B97C52B31 Q37467572-25AB639F-34D7-4EC3-B37C-28CCB2101F50 Q37505384-4FE532B6-949B-4AF7-A202-B496D35361F8 Q37681007-6BAE7550-4593-4510-B739-FD758F991D04 Q37698645-A0A285BE-CD2F-4B3A-81BC-C33337BAECC3 Q37729195-7703BFF9-5D66-40EA-AB2E-AC0937BD86CC Q37773301-DF002B30-1DDD-4397-A314-99A1535F0640 Q38026464-E1627005-839D-4255-A525-E53EB8A06E34 Q38089206-87D57E00-5A48-4268-83CE-46A659542111 Q38836045-5B72A121-31E4-44CF-B2B3-2124C1471742 Q39762419-46D81B63-0434-4287-B99D-46AE5A6204DB Q39922525-1EE443CD-88A5-4DCF-B237-943EE7EB8844

P2860

The paradox of response and survival in cancer therapeutics

http://www.wikidata.org/entity/Q34449433

description

2005 nî lūn-bûn

@nan

2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

The paradox of response and survival in cancer therapeutics

@ast

The paradox of response and survival in cancer therapeutics

@en

The paradox of response and survival in cancer therapeutics

@nl

type

label

The paradox of response and survival in cancer therapeutics

@ast

The paradox of response and survival in cancer therapeutics

@en

The paradox of response and survival in cancer therapeutics

@nl

prefLabel

The paradox of response and survival in cancer therapeutics

@ast

The paradox of response and survival in cancer therapeutics

@en

The paradox of response and survival in cancer therapeutics

@nl

P1433

Q34449433-302CEAAB-CE93-4D4A-9CBF-DDB01F192AAB

P1476

Q34449433-F3399CC6-93D0-4ED0-940B-7398EC16D246

P2093

Q34449433-322841D7-6209-47FF-B4AC-8FF90B1E4F07

Q34449433-A7869B23-1BF9-4804-98F5-25EF565F8668

Q34449433-B67D1AD6-4631-4640-AD3C-57762C73661C

Q34449433-D8440BE0-5681-48B8-99D6-79C799C3D5B3

P2860

Q34449433-096D577C-C6B6-4E57-857C-C8A79DEFC7DD

Q34449433-12A1D997-F758-455C-B8B5-D08890D86C5B

Q34449433-1877843C-FE26-4696-B1E0-348F1660B98B

Q34449433-20693264-7FC9-47B2-BEB4-F483A7D5BA2B

Q34449433-28E78987-FEFB-426E-8123-6F7ED06F3769

Q34449433-2BD194E6-F701-4165-8022-3434E5580D45

Q34449433-2D61F69A-C660-4D7D-A873-899C4B3C1A08

Q34449433-306514A1-F931-4E87-9805-AB97075B12B0

Q34449433-34297D72-8857-4FF4-ABB7-8DC8034E9A07

Q34449433-3C34B89B-02E2-4663-AD9A-109FAAADF1FE

P304

Q34449433-6EF5A468-0BDA-4626-8575-2DBFA8E1C024

P31

Q34449433-04B5A3F4-3C2B-4FEC-A796-C54976206CEF

P356

Q34449433-89BC00B0-82F5-4453-9E5A-6B53EBC9B32F

P407

Q34449433-B3574B7F-B7C5-4E3E-9447-9BDF40519E14

P433

Q34449433-D51FFDA7-B661-41B8-A914-53CB0F862DA3

P478

Q34449433-F5411720-C472-4082-AD83-9AEF296221C6

P577

Q34449433-0A3D4D48-565C-4E0D-9BA3-BB0D9C99B61F

P698

Q34449433-819000CE-C6C7-4EF2-81FE-6AB28C4C6BC5

P932

Q34449433-7E5A1F7D-9E27-43CF-A72A-EA7316AEE726

P356

BLOOD-2005-06-2517

P1433

P1476

The paradox of response and survival in cancer therapeutics

@en

P2093

B Douglas Smith

http://www.w3.org/2001/XMLSchema#string

Carol Ann Huff

http://www.w3.org/2001/XMLSchema#string

Richard J Jones

http://www.w3.org/2001/XMLSchema#string

William Matsui

http://www.w3.org/2001/XMLSchema#string

P2860

Cancerous stem cells can arise from pediatric brain tumors

Characterization of clonogenic multiple myeloma cells

Prospective identification of tumorigenic breast cancer cells

Stem cells, cancer, and cancer stem cells

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

Identification of a cancer stem cell in human brain tumors

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

P304

431-434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-06-2517

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16150939

http://www.w3.org/2001/XMLSchema#string

P932

1895602

http://www.w3.org/2001/XMLSchema#string